IONS Ionis Pharmaceuticals Inc

Price (delayed)

$38.125

Market cap

$5.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.01

Enterprise value

$6.12B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and ...

Highlights
Ionis Pharmaceuticals's EPS has surged by 100% YoY and by 95% QoQ
The net income has surged by 99% year-on-year and by 86% since the previous quarter
The company's equity fell by 8% QoQ but it rose by 4.3% YoY
The company's debt rose by 33% YoY

Key stats

What are the main financial stats of IONS
Market
Shares outstanding
141.8M
Market cap
$5.41B
Enterprise value
$6.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.61
Price to sales (P/S)
6.42
EV/EBIT
1,095.8
EV/EBITDA
268.45
EV/Sales
7.27
Earnings
Revenue
$840.77M
EBIT
$5.58M
EBITDA
$22.78M
Free cash flow
$40.92M
Per share
EPS
-$0.01
Free cash flow per share
$0.29
Book value per share
$5.01
Revenue per share
$5.94
TBVPS
$17.58
Balance sheet
Total assets
$2.52B
Total liabilities
$1.81B
Debt
$1.25B
Equity
$709.57M
Working capital
$2.02B
Liquidity
Debt to equity
1.76
Current ratio
9.86
Quick ratio
9.1
Net debt/EBITDA
31.15
Margins
EBITDA margin
2.7%
Gross margin
98.5%
Net margin
-0.5%
Operating margin
0.5%
Efficiency
Return on assets
-0.2%
Return on equity
-0.6%
Return on invested capital
0.2%
Return on capital employed
0.2%
Return on sales
0.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
0.41%
1 week
2.38%
1 month
1.32%
1 year
-3.6%
YTD
25.29%
QTD
2.93%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$840.77M
Gross profit
$828.34M
Operating income
$4.28M
Net income
-$3.89M
Gross margin
98.5%
Net margin
-0.5%
The operating margin has surged by 114% since the previous quarter and by 102% year-on-year
IONS's operating income has soared by 114% since the previous quarter and by 102% year-on-year
The company's net margin has surged by 99% YoY and by 86% QoQ
The net income has surged by 99% year-on-year and by 86% since the previous quarter

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.61
P/S
6.42
EV/EBIT
1,095.8
EV/EBITDA
268.45
EV/Sales
7.27
Ionis Pharmaceuticals's EPS has surged by 100% YoY and by 95% QoQ
The stock's price to book (P/B) is 28% less than its 5-year quarterly average of 10.5 and 4.1% less than its last 4 quarters average of 7.9
The company's equity fell by 8% QoQ but it rose by 4.3% YoY
The P/S is 34% less than the 5-year quarterly average of 9.7 and 4.6% less than the last 4 quarters average of 6.7
IONS's revenue is up by 19% YoY and by 3.7% QoQ

Efficiency

How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has surged by 129% QoQ and by 104% YoY
Ionis Pharmaceuticals's ROIC has soared by 129% from the previous quarter and by 104% YoY
IONS's return on assets has surged by 99% year-on-year and by 83% since the previous quarter
IONS's return on equity has surged by 99% year-on-year and by 87% since the previous quarter

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 39% greater than the total liabilities
IONS's quick ratio is up by 46% year-on-year
The current ratio rose by 46% year-on-year
The company's debt is 76% higher than its equity
The company's debt rose by 33% YoY
Ionis Pharmaceuticals's debt to equity has increased by 28% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.